Reduction of Chemotherapy Associated Accelerated Aging by ImmortaSome™ Personalized Exosome Rejuvenation

PR Newswire
March 11, 2025
Immorta Bio Unveils Breakthrough Anti-Aging Exosome Therapy

Immorta Bio Inc. has announced a patent filing for its ImmortaSome™ exosome technology, a personalized, stem cell–derived nanoparticle therapy designed to reverse chemotherapy-induced aging. Preclinical studies show promising tissue rejuvenation and reduced cellular aging. By using patient-specific blood to create “young” regenerative cells, Immorta Bio aims to enter clinical trials rapidly, targeting age-related damage and expanding to broader anti-aging applications.

Read Full Article

Explore More

June 5, 2025

Immorta Bio's Anti-Aging Stem Cell Product Shows Superiority in Rheumatoid Arthritis in Preclinical Studies

May 5, 2025

Immorta Bio Presents SenoVax™ Cancer Senolytic Immunotherapy Preclinical Data at American Association of Immunologists Meeting

April 22, 2025

Senescent Cell Removal Unleashes NK Cells Shown to Fight Cancer and Viruses in Animal Models

See all news
Get The Latest News and Developments On Our Longevity Journey
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By subscribing, you are acknowledging your consent to receive  Immorta Bio newsletters
19505 Biscayne Blvd, Ste 2350 Aventura, Florida 33180
305 632-2939
info@immortabio.com